Inhibition of EGF/EGFR signaling by the widely utilized anti-tumor drug gefitinib greatly inhibited TGIF2WT-promoted metastasis of H1299 xenografts as monitored in vivo by the luciferase assay (Fig. 5h, i), which was further confirmed by counting the tumor burden shown by HE staining (Fig. S3b, c). Here, EGFR is linked to neoplasm.